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Abstract 
 
Tissue injury may bring up the systemic participation of bone marrow stem cells in 
the repair. In this study, we report that substance-p is a systemically acting 
messenger to mobilize mesenchymal stem cell (MSC) probably from the bone 
marrow and be engaged in the wound healing process. This was supported by the 
injury-inducible substance-p detection in the tissue and the peripheral blood and 
subsequent MSC mobilization in the alkali-burn rabbit eye model, whose kinetics 
were dependent on the wound size. Furthermore, i.v. injection of exogenous 
substance-p stimulated MSC mobilization in the uninjured rabbits and those 
mobilized cells showed multipotent differentiation capacity. We demonstrated that 
earlier substance-p elevation in the circulation by substance-p injection or 
transfusion of autologous PKH-labeled MSC mobilized by substance-p strongly 
accelerated the wound healing of the alkali-burned rabbit eye and the transfused 
MSCs were engrafted to the epithelial and stromal layer of the injured tissue, 
suggesting their epithelial transdifferentiation in the regenerating tissue. Finally, we 
showed that substance-p stimulated transmigration of human MSC with 
concomitant induction of MMPs and inhibition of their inhibitors, cell proliferation, 
ERK1/2 activation, and nuclear translocation of β-catenin in vitro. In conclusion, 
substance-p plays a role as a systemic wound-messenger to promote the MSC 
mobilization from the marrow and their participation in the wound healing possibly 
through its stimulant effect on MSC repopulation as well.  
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
30
9.
1 
: P
os
te
d 
10
 N
ov
 2
00
7
Introduction 
 
 
Tissue injury may create a unique and specific wound microenvironment 
composed of cytokines, chemokines, growth factors, and neurohormones, which 
are released from the surrounding epithelium, stroma, sensory neuron, and 
peripheral blood due to the injury (1, 2). Some of them are known to activate 
inflammatory response. Others, yet to be identified, may play roles as injury-
specific endogenous factors, which can be sensed by the bone marrow (BM) cells 
or neighboring cells that in turn stimulate their migration to the damaged tissue 
and promote structural and functional repair.  
Many previous reports strongly suggest that BM-derived cells, either by 
endogenous mobilization or transfusion, are actively involved in the repair of tissue 
injury such as myocardiac infarction (MI) (3-6), lung injury (7, 8), skin wound (9-11), 
and liver injury (12). Mainly, it was explored in the context of intravenous supply of 
exogenous G-CSF or GM-CSF to stimulate circulatory mobilization of endothelial 
precursor cells (EPC) (13), HSC (14), and MSC in the ischemic MI, and stromal 
cell-derived factor-1 (SDF-1) dependent EPC homing to the injured tissue (15, 16). 
In the bleomycin-induced lung injury, transfused BM-MSC was shown to be 
transdifferentiated into specific and distinct lung cell phenotypes (8). Thus BM-MSC 
has been already anticipated for their homing to the injured site and subsequent 
tissue-specific transdifferentiation. 
Even though BM-MSC was highly anticipated not only in the mesenchyme 
tissue repair but also in other epithelial or neural tissue, endogenous factors 
specific for their mobilization from the BM and homing to the injured site have not 
been reported yet. However, recent reports such that MSC or MSC like cells are 
frequently detected in tissues other than the BM such as fat tissue (17), wound 
healing tissue (18, 19), and pterygium (20), strongly suggest the existence of 
certain endogenous factors governing MSC trafficking from the BM to the 
peripheral tissue. Those factors may be transiently stimulated during the period of 
the tissue injury and repair or under the certain patho-physiological condition. 
Substance-p (SP) is an 11 amino acid neuropeptide encoded by the 
preprotachykinin-1 (PPT-1) gene and has the same peptide sequence among the 
mouse, the rabbit, and the human (NCBI access #M68909, X62994 and 
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NM013998 respectively). SP preferentially binds to NK-1 receptor (NK-1R) and 
activates G-protein-linked signaling pathway and MAPK/ERK pathway in the spiral 
ganglion neuron, smooth muscle cells, and glioma cells (21-23), leading to its cell 
proliferating effect. Diversity of SP expression in neural system as well as in non-
neural tissue such as BM stromal cells (24), epithelial cells (25), endothelial cells, 
macrophages (26), neutrophiles, and tumor cells (27) leads us to predict more 
extended roles of SP, aside from its pain transmitting neurotransmitter, such as 
neuroimmune modulation (28), the BM fibrosis (29), the tumor cell proliferation 
(21, 22), and the cutaneous wound healing (30-33). The SP’s positive role in the 
wound healing within the local microenvironment was proposed by direct 
innervation of SP-nerve ending in the skin (34) and cornea (35) and SP-
stimulated alleviation of the delayed healing under the trigeminal denervation in 
the eye as well as in the Capsaicin-induced neurotrophic keratopathy (36). 
However the systemic effect of SP has not yet been explored in the context with 
MSC mobilization and their recruitment in the injured tissue.  
In this study, we report that SP was an early injury-inductive factor detected 
in the injured tissue and subsequently in the peripheral blood (PB) after the alkali 
burn injury on the mouse and rabbit eye and its induction kinetic in the circulation 
was dependent on the wound size. In order to address the SP’s role as a 
systemic wound messenger to mobilize MSC, this function of SP was injury-
independently proved by i.v. injection of exogenous SP and subsequent MSC 
mobilization in uninjured mice as well as rabbits. Furthermore, SP’s stimulatory 
role in the wound healing in accordance with its role in the MSC mobilizer from 
the BM was independently proven based on the accelerated wound recovery from 
the alkali-burn on the rabbit eye either by SP i.v. injection just after the injury or by 
autologous transplantation of SP-dependently mobilized MSC (MSCsp). In addition, 
SP’s mechanism on the MSC mobilization and MSC repopulation in the BM was 
further explored in the human MSC. 
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Results  
 
SP as an early injury-inducible factor detected in the injured tissue and in the 
circulation  
Injury-inducible factors in the injured tissue were analyzed in the alkali-
burned murine eyes by RT-PCR analysis (Fig. 1a). SP, IL-1, TNF-α, hypoxia-
inducible factor 1α (HIF-1α) and VEGFR1 were expressed in the injured eye from 1 
day, SCF and Placental growth factor (PIGF) from 3 day, and VEGFR2 from 14 day. 
For systemic analysis of their inductions, ELISA was carried out in the PB sample 
(Fig. 1b). Among the early injury-inducible factors detected in the injured eye, the 
SP peptide was increased 3.2 folds in the PB on 1 day, 4.4 folds on 3 day, and 1.3 
folds on 5 day, comparing to the uninjured control. IL-1 and TNF-α, inflammatory 
cytokines, were also elevated but later and smaller than those of SP. By 
immunohistochemical staining with SP Ab, CD29 Ab, and α−SMA Ab, SP peptide 
was strongly detected in the early injured tissue on 1 day but disappeared mostly 
on 3 day, suggesting its earlier regression in the injured tissue than the termination 
of the inflammatory phase (Supplementary Fig. 1a online). In the fibroplasia 
phase of injured tissue, actively migrating large CD29+ and α-SMA+ fibroblastic 
cells were detected among inflammatory cells (Supplementary Fig. 1b online). 
 
SP-specific mobilization of CD29+ fibroblastic cells into the PB of the 
uninjured mice, possibly from the bone marrow  
From the data such as the injury-inducible SP increase in the PB and 
transient detection of CD29+, α-SMA+ fibroblastic cells in the injured tissue, we 
hypothesized that SP may bring up systemic effect on the BM, probably by 
mobilizing MSC into the PB and then their recruitment to the wound site. In order to 
investigate this role of SP independently from other injury-inducible factors, the 11 
amino acid SP peptide was i.v. injected in the uninjured mice at a dose of 5.0 
nmole/kg, which approximately corresponds to the 100nM after dilution in total 
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blood. Then the CD29+ attached cells, distinguished from the CD29-, CD45+ 
macrophages among the attached PB mononuclear cells, were monitored (Fig. 1c, 
Supplementary Fig. 2 a, b online). Exogenous SP injection stimulated CD29+ cell 
mobilization in the PB approximately fifteen folds 1 day and ten folds 2 day 
comparing to the PBS-injected group, which was blocked by concomitant injection 
of mouse specific NK-1R, blocker, R67850. Initially round-shaped and attached 
CD29+ cells, specifically mobilized by SP injection, turned into fibroblastic 
morphology within 3-5 day culture and all those fibroblastic cells were CD29+, 
CD117+, CD166+, α-SMA+, CD34-, and CD45- based on immunofluorescence 
staining (Supplementary Fig. 2c online), probably corresponding to MSC. This 
result strongly suggests a yet unidentified role of SP as a MSC mobilizer.  
Then, alkaline phosphatase (AP)-conjugated SP peptide was i.v. injected to 
explore the tissue origin of the mobilized CD29+ cells and then AP activity was 
measured in the attached cells of the BM flush (Fig.1 d). Strong AP activity was 
detected among live attached cell clusters of the BM flush at 2 h and 4 h post 
injection, which corresponded to the CD29+ cell clusters based on subsequent 
immunocytochemical staining with CD29 Ab after the cell fixation (Fig. 1e). The AP 
activity detected in the BM flush was contributed by AP-conjugated SP bound to 
the CD29+ cell clusters in the BM flush since SP treatment to cultured human MSC 
did not stimulate any AP activity (Supplementary Fig. 3 online). Thus, the i.v. 
injected SP reached to the BM and bound to the CD29+ cells at least within 2 h 
post injection even though the CD29+ cell mobilization was obvious at 1 day post 
injection in the mouse. 
 
Correlation of the wound-size with SP induction kinetics and subsequent 
CD29+ cell mobilization  
If the injury-inducible SP rise in the PB plays a role as a wound messenger, 
the larger wound may induce the more and the faster SP rise in the PB. In order to 
test this hypothesis, rabbits were alkali-burned either on one site per eye (two 
wounds per rabbit, n= 5 per group) or two sites per eye (four wounds per rabbit, n= 
5 per group) and the SP level in the PB of the same rabbit was sequentially 
monitored up to 72 h post burn (Fig. 2a, b). In contrast to the gradual SP elevation 
in the PB of one wound per eye, two wounds per eye showed maximal level of SP 
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induction even at 1 h post burn, whose level sustained up to 3 day observation 
period. Thus if the bigger the injury was made, the earlier and higher SP induction 
in the PB was achieved.  
Effect of the wound size-dependent SP rise on the CD29+ MSC mobilization 
kinetic was examined by measuring initial time and magnitude of CD29+ cell 
mobilization in the PB from the 10 ml PB of the same rabbit sequentially, 3 day, 5 
day, and 7 day post burn (Fig. 2c). In all the five rabbits with one wound per eye, 
no CD29+ cell was detected in the PB until 5 day post burn but its mobilization 
became obvious 7 day post burn (Fig. 2c) and got bigger 9 day post burn (Fig. 3e). 
However, in all the five rabbits with two wounds per eye (total four wounds per 
rabbit), the CD29+ cell mobilization was clearly observed on 5 day, sustained up to 
7 day (Fig. 2c), and got attenuated 9 day post burn (data not shown). Among them, 
four rabbits except one showed higher CD29+ cell mobilization on 5 day than 7 day 
post burn. Thus the SP induction kinetic (time for maximal induction and duration) 
is determined by the wound-size (Fig. 2b), which in turn positively affects the start 
time and possibly the magnitude of the CD29+ cell mobilization with the 4-5 days 
lag after maximal SP peak in the PB.   
 
Characterization of CD29+ cells in the PB mobilized by SP injection  
SP injection in the uninjured rabbit, similarly to the mouse data (Fig. 1), was 
sufficient enough to mobilize CD29+ cells in the PB at least within 3 days without 
stimulation of CD29- CD45+ macrophage mobilization (Fig. 2d), approximately 80 
folds than in the PBS-injected rabbits (Fig. 2e). In contrast, HSC-CFU in the PB 
was stimulated approximately 2 folds (Fig. 2f). After 4 week culture, all the CD29+ 
attached cells expressed keratin 3 (K3), CD29, and α-SMA (Fig. 2g, h). 
Unexpectedly, SP-dependently mobilized CD29+, CD45-, α-SMA+ fibroblastic cells 
expressed K3, previously known to be a corneal epithelial specific marker, whose 
expression was also confirmed in the Stro-1+ human MSC (Supplementary Fig. 4 
online). The K3-expressing CD29+, CD45-, α-SMA+ fibroblastic cells could be 
differentiated into adipocytes based on the oil red-O staining, into osteoblasts 
based on the alkaline phosphatase activity, into chondrocytes based on the 
lacunae formation and Safranin-O staining (Fig. 2i). Based on their multi-potent 
differentiation capacity as well as their distinct profiles of cell surface markers, the 
CD29+, CD45-, α-SMA+, K3+ fibroblastic cells mobilized by the SP injection were 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
30
9.
1 
: P
os
te
d 
10
 N
ov
 2
00
7
probably multi-potent MSCs, noted as MSCsp in this text in order to distinguish 
MSC (MSCBM) derived from the BM.  
 
Accelerated wound healing along with earlier MSCsp mobilization by SP i.v. 
injection after the alkali-burn  
To further determine the SP’s role as a systemic wound messenger 
positively working on the tissue repair, SP was i.v. injected just after and 1 day post 
burn in the rabbit with one wound per eye which showed gradual reach SP peak in 
the PB, approximately 3 day post burn (Fig. 2b). SP injections markedly 
accelerated the burn recovery as judged by the regain of the surface transparency 
and the disappearance of hemorrhagic regions in the limbus and conjunctiva (Fig. 
3a) and by the histological observations showing full thickness coverage of 
epithelium, well organized vasculature, and ordered array of dense collagen 
bundles, which were closely resembled with those of collateral unburned side of 
the same eyes except the still presence of macrophages and polymorphonuclear 
giant cells just beneath the limbal epithelium, comparing to the PBS-injected burn 
control (Fig. 3b). In contrast, the PBS-injected burn control showed only very thin 
coverage of epithelium, active infiltration of large CD29+ fibroblastic cells and loose 
unorganized collagen fibrils in the stroma, which was similar to the histological 
observation on 5 day in the SP injected group (data not shown). SP injection 
accelerated the initial time of the CD29+, α-SMA+ double positive cell mobilization 
at least 3-4 days earlier than in the PBS-injected burn control (Fig. 3c) but did not 
affect the CD29-, CD45+ macrophage mobilization (Fig. 3d). Multiple PB samplings 
from the same rabbit caused slightly delayed healing comparing to the non-
withdrawn rabbit, probably due to the removal of the mobilized cells by the blood 
sampling (data not shown). Thus, accelerated mobilization of CD29+, α-SMA+ 
CD45- fibroblastic cells (MSCsp) in the PB by SP injection again support that the SP 
is a systemic wound messenger and a wound healing stimulant by its function of 
MSC mobilizer.  
 
SP-dose dependency in the start time of MSCsp mobilization and the 
regression of HSC in the PB 
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SP level in the PB seems to control CD29+ cell mobilization kinetic (Fig. 2b, 
c and Fig. 3c) and also the wound healing rate (Fig. 3a,b). We investigated 
whether SP injection doses can control MSC mobilization (Fig. 3e, f) as well as the 
wound healing rate (Supplementary Fig. 5 online) or not. Only at the SP-dose of 
5.0nmole/kg, CD29+ cell mobilization started from 3 day post burn, at the 
0.5nmole/kg and 0.05nmole/kg from 5 day, and from 7 day in PBS-injected burn 
control (Fig. 3e) and all of those mobilized cells in the PB, even though their 
mobilization time is different, were CD29+, α-SMA+, K3+ MSCsp based on RT-PCR 
analysis (Fig. 3f).  
SP itself seems to retain only minimal effect on the HSC mobilization 
comparing to marked stimulation in the MSCsp mobilization of uninjured rabbit (Fig. 
2f). However SP may indirectly affect HSC mobilization provoked by the tissue 
injury and subsequent inflammation by accelerating MSCsp mobilization and the 
wound healing rate. We examined whether SP injection can affect the injury-
stimulated HSC mobilization kinetic or not (Fig. 3g). In the burn control (SP 
0.0nmole/kg), HSC-CFU in the PB was highest at 5 day and regressed at 7 day, 
corresponding to the start time of MSC mobilization. In the SP injected group, 
kinetic of HSC-CFU in the PB was forwardly shifted, steeply regressed close to the 
basal level on 5 day at SP 5.0nmole/kg, and gradually decayed over the time at SP 
0.5nmole/kg and 0.05nmole/kg. Thus HCS-CFU decay time was affected by the 
MSCsp mobilization time, possibly resulting in the accelerated wound healing rate 
and premature termination of inflammatory phase.  
 
Accelerated wound healing by autologous MSCsp transfusion and their 
epithelial localization in the injured tissue 
The mobilized MSCsp is expected to participate in the regeneration of the 
injured tissue. In order to demonstrate the engagement of MSCsp in the tissue 
repair, cultured autologous PKH-labeled MSCssp (5X106 cells) were transfused to 
the alkali-burned rabbit on 3 day post burn, approximately corresponding to the 
start of MSCssp mobilization by SP 5.0nmole/kg injection. Their engraftment to the 
injured tissue was examined and their effect on wound healing was compared with 
the SP-injected or PBS-injected burn control (Fig. 4). MSCssp transfusion 
accelerated the wound healing similarly to the SP-injected group but much faster 
than in the PBS-injected burn control (Fig. 4a). Full coverage of epithelial layer, 
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similarly to that of the unburned side, was achieved both in the SP-injected and in 
the MSCssp transfused rabbits, comparing to the impaired coverage of the epithelial 
layer of the burn control. Loosely aggregating cells apposed between the epithelial 
layer and the stromal layer of the limbus were frequently detected in the transfused 
group (Fig. 4b), suggesting active upward insertion of the transfused cells from the 
stromal region into the epithelial layer.  
PKH-labeled transfused cells were brightly detected in all the epithelial 
layers as well as in the stroma of the regenerated tissue, depending on the degree 
of the healing rate (Fig. 4c) but no PKH-labeled cell was detected in the uninjured 
collateral side (Fig. 4d). Among the PKH-labeled cells in the tissue, those in the 
stroma still expressed α-SMA but those incorporated in the epithelial layer were 
negative in α-SMA expression (Fig. 4c, α-SMA panel). Thus transfused MSCsp 
seems to lose α-SMA expression capacity after their integration in the epithelial 
layer. In certain region of the stroma, K3-expressing cells without PKH-labeling 
(Fig. 4c, K3 panel), probably corresponding to endogenous MSC mobilized by the 
injury-induced endogenous SP, were also often noted, similarly to those of the burn 
control (Fig. 4e, K3 panel). Most features in the regenerated tissue of MSCsp 
transfused rabbits were similar to those in the SP-injected group (Fig. 4f). 
Transfusion of allogeneic MSCSP or MSCBM also accelerated wound healing as well 
as epithelial integration (Supplementary Fig. 6, 7 online) 
 
SP-dependent transmigration of human MSCs with concomitant induction of 
proteolytic enzymes  
 How can SP induce the migration of MSC attached on the marrow stroma? 
To explore the mobilization mechanism, human MSCs were plated on top of 
collagen gel and SP was applied to the bottom dish. SP stimulated transmigration 
of human MSC in a dose dependent manner (Fig. 5a) and along with concomitant 
induction of MMP-2 and MMP-9 (Fig. 5b). Complete migration of human MSC in 
the upper chamber took approximately 3 days. Then to determine whether human 
MSC migration is SP-specific and chemo-attractive one or not, NK-1R blocker, 
L732138 specific for human NK-1R, was concomitantly applied or SP-gradient was 
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abolished by application of the same concentrations of SP in both sides of the 
chamber (Fig. 5c). The SP-dependent transmigration of human MSC was 
specifically inhibited by its receptor blocker and partially blocked by abolishment of 
the SP-gradient.  
Effect of SP on biosynthesis of MMP-1, MMP-2, MMP-9, Tissue inhibitor of 
MMPs (TIMP)-1, and TIMP-2 was examined in the culture medium of 35S-
methionine labeled human MSCs (Fig. 5d). Biosynthesis of MMP-1, MMP-2, and 
MMP-9 was stimulated by the SP but their inhibitors such as TIMP-1 and TIMP-2 
were inhibited by the SP in a dose dependent manner.  
Membrane type-1 matrix metalloproteinase (MT1-MMP) is known to make 
the activation-processing trimeric complex with TIMP-2 and MMP-2 for the 
activation-cleavage of proMMP-2 (38), which was also elevated by the SP in a 
dose dependent manner based on the western blot (Fig. 5e) and 
immunofluorescence staining (Fig. 5f). In the immunoprecipitation of the cell lysate, 
the cell-associated TIMP-2 was not reduced by SP treatment even though their 
detection in the supernatant was decreased and the cell-associated MMP-2 was 
increased by the SP treatment, suggesting trimeric activation cleavage complex 
with MT1-MMP. Thus, SP stimulated human MSC to shift the proteolytic balance 
favorable for the collagen degradation by increasing matrix degrading molecules 
and concomitantly decreasing their inhibitors, which in turn makes a favorable 
environment for MSC mobilization.  
 
SP-stimulated cell proliferation, ERK1/2 activation, and nuclear translocation 
of β-catenin in human MSC  
 If SP retains only the capacity of MSC mobilization from the BM, the BM 
stroma may become empty in the MSC pool after their mobilization. Thus, the SP 
effect was examined in the cultured human MSC at the aspect of cell proliferation 
and self–renewal capacity (Fig. 6). SP increased the number of viable cells (Fig. 
6a) and BrdU incorporating cells (Fig. 6b) in a dose dependent manner. Then, it 
was investigated whether the ERK-1/2 activation is involved in the SP-stimulated 
cell proliferation or not (Fig. 6c-e). When SP was treated at the same time with 
fresh MSCGM change, ERK-1/2 activation was observed in both control culture 
and SP-treated culture at 15 min and 30 min but was sustained up to16 h post 
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treatment only in the SP treated culture, indicating that the serum-stimulated ERK-
1/2 activation, overlapped at earlier time with SP-stimulated one, had completely 
returned to the basal level at 16 h but the SP-stimulated effect still remained (Fig. 
6c). In order to investigate the ERK1/2 activation contributed only by SP treatment 
without overlapping ERK1/2 activation by the fresh medium change at early time 
point, SP was treated to human MSCs at 24 h after the fresh medium change, 
corresponding to the time when the serum-stimulated ERK-1/2 activation has been 
regressed to the basal level. Then, the time course of ERK-1/2 activation was re-
examined (Fig. 6d). The SP-stimulated Erk-1/2 activation was initially detected at 
30 min and regressed to basal level at 1 h and then much bigger ERK-1/2 
activation reappeared at 16 h and again at 48 h, both of which were suppressed by 
MEK inhibitor PD98059 (Fig. 6e). This late and biphasic pattern of ERK-1/2 
activation was probably not due to the SP-stimulated up-regulation of NK-1R in 
human MSC (Fig. 6f) or the persistent presence of SP in the culture medium (Fig. 
6g).  
In order to determine if SP affects the self-renewal capacity of human 
MSCs, β-catenin, a down stream effector of the wnt signaling pathway (39-41), 
was examined (Fig. 6h). At 16 h post treatment, β-catenin was mainly observed in 
the cytoplasm of human MSCs but small numbers of human MSCs only at 100 nM 
showed nuclear localization of β-catenin (data not shown). At 48 h post treatment, 
nuclear translocation of β-catenin was distinct particularly at 100 nM SP and 
almost all the human MSCs showed nuclear translocation of β-catenin (Fig. 6h, 
arrows). This SP-stimulated nuclear translocation of β-catenin was also confirmed 
when SP was treated under the serum-starved condition (Supplementary Fig. 8 
online). The induction of down stream genes of Tcf/β-catenin such as fibronectin 
(41) and VEGF was also shown by western blot analysis (Fig. 6i) and ELISA (Fig. 
6j), respectively. This suggests that SP may play an additional role in the 
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repopulation of MSCs in the BM by stimulating self-renewal capacity via the well-
known canonical wnt signaling pathway. (39). This event might be prerequisite for 
MSC mobilization, which took approximately 3 day after SP injection in the rabbit. 
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Discussion 
 
Recent several reports regarding SP’s diverse roles on the neuro-immune 
network in the BM (42), tumor cell proliferation (21, 22), BM fibrosis (29) and 
corneal-reepithelialization (32, 33) have been explored within the local environment 
of direct cellular contacts. Our finding in this study that SP may play roles as a 
messenger of the tissue injury as well as a MSC mobilizer from the BM opens up 
yet unidentified novel function of SP, acting systemically as a remote controller for 
the BM MSCs to be engaged in the tissue regeneration process. This function of 
SP was expected and supported from data; early detection of immunoreactive SP 
and its gene expression in the injured site, SP-detection in the PB and the wound 
size dependency of its induction kinetic, SP-dependent mobilization of CD29+ MSC, 
and stimulation of wound healing by exogenous SP injection or MSCsp cell 
transfusion after the alkali-burn on rabbit eye. In addition, the mechanism of SP-
stimulated MSC mobilization from the BM was revealed in vitro by the 
transmigration of human MSC with concomitant induction of proteolytic enzymes 
and their BM origin also supported by detection of the injected AP-conjugated SP 
on the CD29+ cell clusters of the BM flush. As expected from previously reported 
function of SP on the cell proliferation (22), SP stimulated ERK1/2 activation and 
nuclear translocation of β-catenin, which may then contribute to MSC repopulation 
in the BM to refill up the BM stroma. This is the first report that SP is a systemically 
acting wound messenger starting from the injured site, then to the circulation, and 
finally to the BM in order to mobilize the MSC from the BM stem cell reservoir into 
the circulation and to recruit to the injured area for tissue repair. 
The SP, as a systemic messenger of the tissue injury, seems to be very 
specific to MSC mobilization. We demonstrated that the SP level in the PB is injury-
inducible in the mouse (Fig. 1a, b) and also dependent on the wound size in the 
rabbit (Fig. 2b) and this injury-inducible SP or exogenous SP regulates MSCsp 
mobilization kinetic (Fig. 2c, d and Fig. 3c, e). The specificity of SP on the MSC 
mobilization was shown by the data that exogenous SP treatment did stimulate 
HSC mobilization only 2 folds, comparing to 80 folds induction in MSC mobilization 
(Fig. 2e,f) and also did not stimulate macrophage mobilization (Fig. 2d and Fig. 
3d). Furthermore, MSC mobilization in the PB seems to attenuate HSC-CFU 
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increase in the PB which is probably stimulated by the injury itself (Fig. 3g). All of 
those data strongly support that the SP is a specific MSC mobilizer. 
The SP peptide at the early wound site may be initially provided by the 
corneal resident cells such as the trigeminal sensory neuron, epithelial cells, 
keratocytes, and endothelial cells but not by the infiltrating neutrophiles or 
macrophages since SP was detected at early stage of the inflammatory phase, 
disappeared in the injury site, and reappeared in the fibroplasia phase mainly 
among the migrating epithelial cells, endothelial cells and fibroblastic cells 
(Supplementary Fig. 1 online). The wound size-dependency of SP kinetic in the 
PB (Fig. 2b) indirectly suggests that the SP in the wound site may be released into 
the circulation as a systemic injury messenger. However possible role of other late 
inflammatory cells or macrophages on SP secretion in the circulation as a 
secondary event initially starting from the SP in the wound microenvironment 
remains unresolved. 
SP’s role on neuro-immune communication was examined on 
hematopoietic modulation through its effect on stromal MSC (42), expected from 
innervation of SP nerve fibers in the BM stroma, expression of NK-1R in the BM 
MSC, and SP-dependent induction of SCF and IL-1 (28). However, circulatory SP’s 
effect on the systemic mobilization of MSCs has not yet been reported previously. 
Furthermore, SP-stimulated nuclear translocation of β-catenin and cell proliferation 
(Fig. 6) strongly suggest a more extended role of SP in the control of the MSC pool 
in the BM. These may also be important for the MSC repopulation after their 
mobilization as well as their ultimate feeder roles in the maintenance of 
hematopoietic microenvironment in the BM. Therefore, the systemic neuro-immune 
modulation from the injury inducible SP on hematopoiesis also has to be 
reconsidered in addition to its reported function on neuro-immunune modulation 
through the direct contact with SP nerve fibers (42). 
The CD29+ attached fibroblastic cells in the PB, which were mobilized by 
exogenous SP injection (Fig. 1c and Fig. 2d, e) or the injury inducible endogenous 
SP (Fig. 2 c), were MSCs probably derived from the BM. Our data of iv injected 
AP-conjugated SP’s binding to the CD29+ cell clusters of the BM flush 2 h post 
injection (Fig. 1d,e), suggests BM as a possible source of circulatory CD29+ cells 
mobilized by SP injection. Distinct surface expression profiles of CD-29+ cells in the 
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PB from those of macrophages, HSC, and EPC and their acquisition of fibroblastic 
morphology after the culture (Fig. 2g,h and Supplementary Fig. 2 online) and 
multi-potent differentiation capacity (Fig. 2i) strongly support that those CD29+ cells 
in the PB were MSC mobilized probably from the BM. However our data of 
constitutive K3 expression in the circulatory CD29+ cells (Fig. 2g.h) and their 
preferential integration into the entire epithelial layer of the injured tissue after the 
transfusion (Fig. 4c) were not previously expected as known characteristics of 
MSC from the BM. This epithelial integration might occur through two events of the 
cell fusion and/or transdifferentiation as shown in the injured airway epithelium (43), 
the lung injury (7, 8), liver injury (12), and skin injury (9-11) but was not explored in 
detail in this study since molecular probes are quite limited in the rabbit. However, 
considering several previous reports on the epithelial transdifferentiation of MSC 
especially under the injury environment (43) and expression of other keratins in 
MSC under certain condition (9, 44) in addition to our data of K3 expression in 
human MSC as well as MSCsp, MSC may have already retained the potential for 
epithelial transdifferentiation operating only transiently within the wound 
microenvironment.  
Even though SP’s importance on the wound healing has previously been 
suggested in the corneal wound healing (32, 33) and diabetic ulcer (31), it was 
mainly explored within the proximity of the injured site. Our data that MSC was 
mobilized into the PB by systemically injected SP or by injury-induced endogenous 
SP and the wound healing was accelerated by SP i.v. injection or the transfusion of 
MSCsp also accelerated the wound healing, strongly supports that the mobilized 
CD29+ cell, probably MSC from the BM, is an active participant for tissue 
regeneration. This new function of SP as a MSC mobilizer also has to be 
considered as a systemic injury messenger since this SP rise was initially 
recognized in the injured tissue just after the tissue damage.  
In this study, factors responsible for trafficking of the CD29+ cell to the 
injured tissue were not investigated but those factors such as HIF-1, SCF, PIGF, 
and VEGF noted by RT-PCR and ELISA (Figure 1 and data not shown) might be 
explored for possible candidates in the future study. However those well 
established mechanisms on SDF-1 dependent homing to the myocardially infracted 
tissue (15) after G-CSF stimulated EPC mobilization may not work in the CD29+ 
cell homing to the injured tissue since most MSCs except a minor subset do not 
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express CXCR-4 (45).  
Normative lag time for circulatory mobilization of MSCsp in the rabbit might 
be approximately 3 days after the SP’s peak in the circulation, similarly to the 
clinical protocol of the G-CSF stimulated CD34+ progenitor mobilization, 
approximately 4-5 days. Under in vitro transmigration assay, SP-stimulated 
migration of human MSCs took approximately 3 days to accomplish the 
transmigration. Our biochemical data such as SP-stimulated cell proliferation, Erks 
activation, β-catenin nuclear translocation observed in human MSC, and AP-
conjugated SP binding as early as 2 h post injection in the mouse strongly 
suggested that those sequential events ultimately lead to MSC mobilization from 
the BM during the lag period. In contrast, shorter lag time, approximately one day, 
was shown in the mouse, which may be reflected by the difference in species and 
body size.  
SP is known to bind to the cell surface G-protein coupled receptor (GPCR), 
NK-1R and elicits a variety of responses such as inflammation and cell proliferation 
in T lymphocyte, skin fibroblasts, smooth muscle cells, and synoviocyte (46-48). 
Those pleiotrophic responses may be based on the GPCR mediated 
transactivation of the EGFR and subsequent ERK1/2 activation as previously 
reported in GPCR signaling pathway such as vassopressin and VIP (21-23). In this 
study, biphasic late ERK1/2 activation observed at 16 h and 48 h may not be due 
to the continuous and sustained activation of NK-1R since only 1/200 and 1/300 of 
the original SP dose in the case of 100nM SP were left 24 h and 48 h after the SP 
treatment respectively and NK-1R expression was fairly constant based on the 
western blot analysis during the SP treatment. This may be rather due to the 
secondary factors released by the primary SP response, which remains to be 
explored. The interrelationship between ERK1/2 activation, MMP induction, and 
cell migration, has to be determined but several previous reports strongly 
suggested that those sequential events might be plausible.  
The high level of SP and NK-1R is associated with the metastatic and 
malignant phenotypes in several cancer cells (21, 22). Newly identified roles of SP 
in cell mobilization, MMP induction, cell proliferation, and possibly the β-catenin 
mediated self renewal capacity are also expected to interplay in the tumor 
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metastasis. Therefore, side effects such as neuro-inflammatory (49) effect  and 
metastatic stimulation of SP, in addition to it’s promising effects such as a wound 
healing agent and a cell therapeutic MSC mobilizer, needs to be considered and 
finely regulated for future clinical applications.   
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Materials and Methods 
 
Materials  
Primary human MSCs, mesenchymal growth medium (MSCGM; PT-3001), and 
chondrogenic differentiation medium (PT-3003), adipogenic induction medium (PT-
3004), osteogenic induction medium (PT-3002) were purchased from Cambrex Bio 
Science. SP peptide, AP-conjugated SP, gelatin, and Millicell were purchased from 
Calbiochem, R&D system, Becton Dickinson, and Millipore respectively. Abs 
against CD34 (Cat # sc-9095), CD-29 (Cat # sc-6622, 1:200), c-kit (Cat # sc-1493, 
1:100), CD45 (Cat # sc-1121, 1:50), CD 166 (Cat # sc-25624, 1:100), NK-1R (Cat # 
sc-15323, 1:100) and SP (Cat # sc-9758, 1:200) were purchased from Santa Cruz 
Biotechnology and Abs against α-SMA(DAKO, Cat # M0851, 1:50), CD105(DAKO, 
Cat # M3527, 1:50), CD44 (DAKO, Cat # M7082, 1:100), CD29 (DAKO, Cat # 
M0889, 1:100), and STRO-1 (R&D, MAB1038, 1:150), K3 (ICN, Cat # 69143, 
1:200), β-catenin (BD, Cat # 610154, 1:100), ERKP (Cell signaling Cat # 9102, 
1:500), pan-ERK (BD Cat # 610123, 1:500) were purchased. The Abs against 
TIMP-1 (Cat # IM32L, 1:250), TIMP-2 (Cat # IM11L, 1:250), and MMP-9 (Cat # 
444236, 1:100) were acquired from Calbiochem. The Abs against MMP-2 (Cat # 
MAB13405, 1:200) and MT1-MMP (Cat # MAB3319, 1:100) were purchased from 
Chemicon. ELISA kits for SP, VEGF, TNF-alpha, and IL-1beta were purchased from 
R&D system. Primary Abs were detected using ABC KIT, FITC or Texas Red-
conjugated secondary antibodies (Vector), and HRP-conjugated secondary 
antibodies (Biorad). PKH red fluorescent cell linker kit (Cat # MINI26) was 
purchased from Sigma Chemicals. Type I-A collagen and type IV collagen were 
purchased from Nitta gelatin (JP). NK-1R blocker, RP67580 (Cat # 1635) and 
L732138 (Cat # 0868) were purchased from TOCRIS. HSC-CFU media (Cat # 130-
091-280) was purchased from Miltenyi. 
  
Alkali-burn eye animal model 
Balb/c mouse weighing 25-30g were purchased from Jackson Lab (West Grove, 
PA) and New Zealand white rabbits weighing 2-3kg were purchased from Samtako 
BioKorea. All the animal experiments were approved by the ethical committees for 
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experimental animals of the Kyunghee University and the Chung-Ang University 
and conducted in accordance with the ARVO Statement for the Use of Animal in 
Ophthalmic and Vision Research. For the alkali burn, mouse eyes were placed in 
contact with the circular Whatman filter paper (3mm diameter) or Q-tips soaked in 
1N NaOH for 10 seconds and excess NaOH rinsed out with the saline irrigation. 
For rabbits, the alkali burn was made with the circular filter paper (6 mm diameter) 
soaked in 1N NaOH for 10 seconds (Fig. 2a) and as previously described(18).  
 
RT-PCR analysis 
The RNA was isolated from the alkali burned mouse eye by Trizol (Cat # 15596-
026, Invitrogen, Carlsbad, CA). A total of 1μg RNA was reverse transcribed (RT) 
using a reverse transcription-polymerase kit (Takara), which was followed by PCR 
using mouse gene-specific primers:  
VEGF (expected size: 407), (sense) 5’GTACCTCCACCATGCCAAGT3’, 
(antisense) 5’AATGCTTTCTCCGCTCTGAA 3’,  
TNF-alpha (expected size: 438), (sense) 5’GAACTGGCAGAAGAGGCACT3’, 
(antisense) 5’GTGGGTGAGGAGCACGTAGT3’,  
IL-1 (expected size: 432), (sense) 5’GCTGCTTCCAAACCTTTGAC3’, (antisense) 
5’AGGCCACAGGTATTTTGTCG3’,  
SP (expected size: 309), (sense) 5’TCGATGCCAACGATGATCTA3’, (antisense) 
5’AGTTCTGCATTGCGCTTCTT3 
HIF-1 alpha (expected size: 297), (sense) 5’GAAATGGCCCAGTGAGAAAA3’, 
(antisense) 5’TATCGAGGCTGTGTCGACTG3’ 
VEGFR-1 (expected size: 414), (sense) 5’CTCAAGTGTCACCAGCTCCA3’ 
(antisense) 5’GGGTATGGAGAACCCCCTAA3’ 
VEGFR-2 (expected size: 430), (sense) 5’CTGGGAGCTGGAAGACAAAG3’ 
(antisense) 5’GTACCTCCACCATGCCAAGT3’ 
PlGF (expected size: 287), (sense) 5’TGCTGGTCATGAAGCTGTTC3’ (antisense) 
5’GCTGTCTTTATCGGCACACA3’ 
SCF (expected size: 329), (sense) 5’CCTCTCGTCAAAACCAAGGA3’ (antisense) 
5’GGCCTCTTCGGAGATTCTTT3’ 
β-actin (expected size: 415), (sense) 5’TGTTACCAACTGGGACGACA3’ 
(antisense) 5’TTTGATGTCACGCACGATTT3’ 
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For the rabbit MSCsp, the RNA isolation and RT-PCR were followed as described 
above using rabbit gene-specific primers:  
α-SMA (expected size: 455), (sense) 5’TTTCAATGTCCCAGCCATGT3’  
(antisense) 5’ATTCCATCCCGATGAAGGAG 
CD29 (expected size: 473), (sense) 5’TGTATACAAGCAGGCCCCAA3’ (antisense) 
5’ TTCTCTGCTGTGCCTTTGCT3’  
K3 (expected size: 314), (sense) 5’ CTCAATGTGGAGATCGACCC3’ (antisense) 
5’ AGGTCCTGCATGCTTCTCAG3’   
GAPDH (expected size: 459), (sense) 5’ GAAGGTCGGAGTGAACGGAT3’ 
(antisense) 5’ TGCGTTGCTGACAATCTTGA3’ 
  
SP-dependent CD29+ cell mobilization   
SP (5nmole/kg) was i.v. injected into the mouse tail vein or rabbit ear vein and the 
blood was collected at the indicated time. After removing red blood cells by Ficoll 
gradient centrifugation, mononuclear cell fraction was allowed to attach for 1 day 
and unbound lymphocytes were removed at the first medium change. The attached 
cells were either fixed for immunocytochemical staining or further cultured in 
MSCGM until obvious fibroblastic morphology and cell growth resume. The cells 
were stained with mouse specific Abs against CD29, CD166, CD117, α-SMA, 
CD34 and CD45 or rabbit specific Abs against CD29, α-SMA, CD45, and K3 and 
subsequently detected by FITC or Texas Red conjugated secondary Abs. For the 
specificity confirmation of CD29 and CD45 as surface markers to distinguish MSC 
from macrophage among attached PB cells, mouse peritoneal macrophage was 
used.   
 
AP-conjugated SP binding to the BM cells 
AP-conjugated SP was i.v. injected to mouse tail vein and at 0 h, 2 h, and 4 h post 
injection, mouse femur was irrigated with collagenase solution and the isolated 
cells were allowed to attach in MSCGM for 24h. AP activity was measured 
according to the manufacturer’s specifications (Sigma Chemical) and after 
examination of AP activity, the cells were fixed for immunocytochemical staining 
with CD29 Ab. In order to rule out endogenous AP activity and also SP-stimulated 
induction of AP activity in the BM-MSC, human MSCs purchased from Cambrex 
were treated with SP and their AP activity was measured as described above.  
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The wound-size dependency of the SP induction and MSC mobilization  
One wound per eye (total two wounds per rabbit) or two wounds per eye (total four 
wounds per rabbit) were made as shown in Figure 2a. For two wounds per eye, 
both wounds were made on the upper part of the eye with approximately 90 degree 
separation not to overlap with the muscular tendon of the middle line. For ELISA of 
SP in the serum, 1.5ml of PB was collected at 1h, 6h, 24h, 48h and 72h post burn 
from the same rabbit. To monitor the numbers of MSC in the PB, 10ml PB was 
collected sequentially at 3, 5 and 7 days post burn from the same rabbit and the 
CD29+ attached cells were counted after the two week culture.  
 
Effect of SP i.v. injection on MSC and HSC mobilization and on the wound 
healing    
One wound per eye (3 per group) was made as described above and SP at doses 
of 0.05 nmole/kg, 0.5 nmole/kg, 5.0 nmole/kg were i.v. injected twice just after the 
injury and 1 day. PB 10ml was collected at 0, 3, 5, 7, 9 days from the same rabbit 
and mononuclear cells were isolated by Ficoll gradient centrifugation. For MSC 
counting, the cells were allowed to be attached and after removal of lymphocytes 
were cultured in MSCGM for 2 weeks and fixed in 4% paraformaldehyde. Double 
immunofluorescence staining for CD45 and CD29 and for α-SMA and CD29 along 
with DAPI staining was performed. CD29+ cells were counted For HSC-CFU assay, 
the cells were cultured HSC-CFU media for 2 weeks and colonies were counted. 
For molecular characterization of the mobilized cells, RT-PCR and 
immunofluorescence staining was performed as described above. Effect of SP 
injection on the wound healing was monitored by Digital camera and by H&E 
staining of the fixed tissue.  
  
Multipotent differentiation capacity of the mobilized CD29+ cells 
For multi-potent differentiation capacity test of mobilized cells, the cells from SP 
injected 3 day post burn were subcultured in MSCGM for 4 weeks. All the 
macrophages were removed at the first passage by trypsin sensitivity. For 
adipogenic differentiation capacity, 2x105 cells/well were cultured in DMEM-high 
glucose (Gibco) supplemented with 0.5 mM 1-methyl-3-isobutylxanthine (Sigma), 
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1 μM dexamethasone (Sigma), 10 μg/ml insulin (Sigma), and 10% FBS for 21 days 
and the fixed cells were stained with oil red “O”. For osteogenic differentiation 
capacity, 4x104 cells/well were cultured in DMEM-high glucose (Gibco) 
supplemented with 1 μM dexamethasone (Sigma), 0.05 mM ascorbic acid (Sigma), 
10 mM β-glycerophosphate (Sigma), and 10% FBS for 21 days and stained with 
Alizarin red. For chondrogenic differentiation capacity, 5 x105 cells/well were 
incubated in chondrogenic differentiation medium (Cambrex) in 15ml polystyrene 
tube for 4 week and the chondrocyte pellets were fixed with 4% paraformaldehyde 
for 48h. The sections were stained in Weigert’s iron hematoxylin and Safranin-O. 
As a positive control, the same induction was applied to human MSC. 
 
Autologous MSCsp transfusion 
The SP-stimulated mobilized cells were isolated from the 3 day PB of unburned 
rabbits and were individually cultured for 4 weeks. For PKH-labeling, cells were 
prepared in a conical bottom polypropylene tube and washed once using serum-
free medium and labeled using PKH red fluorescent cell linker kit (Sigma) 
according to manufacturer’s specifications. At 3 day after the burn injury, 
approximately corresponding the start time of MSC mobilization after the SP 
injection, PKH labeled cells (5x106 cells) were transfused through the rabbit ear 
vein. At 7 day, all the rabbit were sacrificed and the eyes were embedded in OCT. 
Frozen sections (5 μm) were incubated with either K3, CD29, and α-SMA Ab after 
blocking with normal goat serum and then with FITC-conjugated secondary 
antibodies. After DAPI staining, sections were mounted with vector shield and PKH 
labeled cells and FITC labeled cells were observed immediately with fluorescence 
stereomicroscope (Leica) or confocal microscope (Zeiss) 
 
Cell culture  
Human MSCs (Cambrex) were cultured in the MSCGM and the medium was 
changed every three days. The MSCs between passage 4 and 6 were used for all 
the in vitro experiments and their identity was confirmed at each passage by the 
expression of CD105, CD44, CD29, and STRO-1. 
 
In vitro cell migration assay 
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The type I collagen gel matrix was made within a 12 mm millicell membrane (12-
μm pore size) according to the manufacturer’s specifications (Nitta gelatin, Japan) 
and coated overnight with type lV collagen (Nitta gelatin). The MSCs were plated 
on top of the collagen gel. SP and human specific NK-1R blocker, L732138 (100 
nM) were treated either in the upper or the bottom chamber. The clearance of the 
collagen gel was examined. The millicell inserts were fixed 3 day, and stained with 
H&E. The culture supernatants were saved for the gelatin zymography. 
 
Gelatin zymography 
The culture supernatant was resolved in the 8 % SDS-PAGE under non reducing 
condition, the gel was renatured with 2.5% Triton x-100 to order to remove the SDS, 
incubated with a developing buffer (50 mM Tris-HCl, pH 7.2 100 mM NaCl, 20 mM 
CaCl2) at 37°C overnight, and the gel was stained with Coomassie blue.  
 
Metabolic cell labeling and immunoprecipitation 
Human MSCs were treated with SP and labeled with 50 μCi/ml 35S-methionine 
(Amersham) for 16 h. The cell lysate was prepared with a lysis buffer (1% NP40, 
10 mM Tris-HCl, pH 7.4, 150 mM NaCl. 1 mM EDTA, 2 mM PMSF). For 
immunoprecipitation of the secreted MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2, 
the culture supernatants were incubated with their specific antibodies for 2 h under 
constant rotation and the antibodies were collected by protein-G sepharose-4B 
(Biorad). The pellet was washed three times with an immunoprecipitation buffer 
(150 mM NaOH, 50 mM Tris-HCl pH 7.4, 0.2% SDS and 0.5% Nadeoxycholate), 
once with a high salt buffer (10 mM Tris-HCl, pH 7.4, 0.5 M NaCl), and once with a 
low salt buffer (10 mM Tris-HCl, pH 7.4). After SDS-PAGE, the gel was soaked in 2 
M sodium salicylate, dried, and exposed to the X-ray film for 2 weeks. For 
immunoprecipitation of MT1-MMP, membrane bound MMP-2, TIMP-2, and TIMP-1, 
the cell lysate was incubated with specific primary antibodies and the remaining 
procedures were the same as described above. 
 
Western blot analysis 
Human MSCs were lysed with the lysis buffer containing 50 mM sodium vanadate. 
After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane at 
250 mV for 2h. The membrane was blocked with 5% skim milk (Becton Dickinson), 
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incubated with the antibodies against MT1-MMP, phospho-ERK, pan-ERK, NK-1 R, 
and α-tubulin for 90min, and developed by a the chemiluminescence detection kit 
(NEN) 
 
BrdU labeling  
Human MSCs were cultured with SP on cover slip for 24h and 48h. BrdU was 
added to humans MSCs at 2h before the cell harvest. Humans MSCs was fixed 
with absolute methanol for 10min and DNA was denatured by incubation with HCl 
(2M) for 60min. For neutralization, cover slips were immersed with Borate buffer 
(0.1M, pH 8.5) twice over a 10min period and washed with PBS three times. Cover 
slips were incubated with anti-BrdU antibody for 60min at RT and then with the 
FITC-conjugated secondary antibodies. The cells were counterstained with DAPI 
and examined with confocal microscope (Leica) 
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Figure legends 
 
Figure 1 SP-expression in the alkali-burned mouse eye, subsequent SP-detection 
in the PB, and SP-stimulated mobilization of CD29+ cells from the BM. (a) RT-PCR 
analysis of the injured mouse eye and (b) ELISA of the PB at the indicated time 
after the alkali burn on mouse eye. Results shown are mean values + s. d. (n=4 at 
indicated time point). (c) SP-stimulated mobilization of CD29+ cells and its 
inhibition by NK-1R blocker RP67580 in uninjured mice. SP at dose of 5.0nmole/kg 
was i.v. injected and the whole blood was withdrawn with heparin-coated syringe. 
After removal of unattached lymphocytes, round shaped and large attached CD29+ 
cells were counted (Supplementary Figure 2 online). For the analysis of SP 
specificity, NK-1R blocker RP67580 (0.5 μmole/kg) was co-injected with SP. 
Results shown are mean values + s. d. (n=5 at the indicated time point).  *P< 0.05 
**P < 0.01, ***P < 0.001 versus the PBS-injected control. I indicated coinjection of 
NK-1R blocker RP67580. (d, e) SP-binding on the attached CD29+ cell clusters of 
the BM flush. AP-conjugated SP was i.v. injected and the BM flush from the tibia 
were collected at 0h, 2h, and 4h.  After attachment of the BM flush, AP activity 
was measured in live cells. For detection of AP activity within the CD29+ cell 
clusters of the BM flush, the same cover slip was fixed after AP color development 
and stained with CD29 Ab. Scale bar=100μm.  
 
Figure 2 Wound-size dependency of SP induction in the PB and CD29+ cell 
mobilization in the alkali-burned rabbit, SP-specific mobilization of CD29+ cells in 
uninjured rabbit, and their reveal of multipotent MSC phenotype. (a) Alkali-burn 
rabbit eye model. One wound per eye (total two wounds per rabbit) or two wounds 
per eye (total four wounds per rabbit) were made by contacting the 1.0 N NaOH 
soaked circular paper. The injured site was noted as a white circle with 
hemorrhagic area. (b) Comparison of SP induction kinetics between two wound 
group (n= 5) and four wound group (n=5). Unburned rabbit as negative control 
(n=3). Results shown are mean values + s. d. (c) Comparison of CD29+ cell 
mobilization kinetics between two wound group (n=5) and four wound group (n=5). 
10 ml PB was withdrawn sequentially from the same rabbit at the indicated time 
and CD29+ fibroblastic cells were counted after the acquisition of fibroblastic 
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morphology for 15 day culture. In two wound per eye, all five rabbits showed 
CD29+ cell mobilization in the PB at 5 day after the injury but no rabbit in one 
wound per eye showed CD29+ cell mobilization at this time point. RB; rabbit (d) 
SP-stimulated mobilization of CD29+, CD45- fibroblastic cells in uninjured rabbit 
without stimulation of CD29-, CD45+ macrophage. SP at dose of 5.0nmole/kg was 
i.v. injected twice and 10 ml PB was collected on 3 day and 7 day. After acquisition 
of fibroblastic morphology, double immunofluorescence staining with anti-CD45 
(Texas Red; red) and anti-CD29 (FITC; green) was done. At 3 day after SP 
injection, CD29+ cells were detected in the PB of uninjured rabbits. All the CD29+ 
cells were negative in CD45 and CD45+ macrophage in the PB did not increase.  
(e) Quantitative comparison of SP-stimulated mobilization of CD29+, CD45- 
fibroblastic cells and (f) HSC-CFU. The PB was withdrawn 3 day after SP injection. 
CD29+ attached cells after 14 day culture and HCS-CFU was counted. Results 
shown are mean values + s. d. (n=5 in each group). (g) Molecular characterization 
of CD29+, CD45- cells mobilized by SP injection in the uninjured rabbit by 
immunofluorescence staining, (h) by RT-PCR, and (i) by multipotent differentiation 
capacity. The CD29+ cells mobilized into PB at 3 day after SP injection were 
cultured 4weeks. Macrophages were removed at first passage by their less 
sensitivity to trypsin. All the CD29+ cells were α-SMA+, CD45-, K3+ cells, which 
could be differentiated into adipocyte, osteoblast, and chondrocyte (n=4 in each 
group). Human MSC was used as a positive control. Scale bar=100μm.  
 
Figure 3 Accelerated wound healing by SP injection was accompanied by 
accelerated MSCsp mobilization and earlier regression of HSC-CFU in the PB. One 
wound per eye was made and SP or PBS was injected twice just after the burn and 
1 day post burn at the dose of 5 nmole /kg. (a) Gross view of wound healing and 
(b) histological comparison between SP injected and PBS injected group (n=3 in 
each group). The original wound size was noted by the dotted circle. In the SP 
injected rabbit, transparent corneal surface with no hemorrhagic zone was 
observed, comparing to persistence of hemorrhagic zone in the PBS-injected rabbit. 
Macrophages and polymorphonuclear giant cells just beneath the limbus 
epithelium of the SP-injected group were noted (*) and actively infiltrating CD29+ 
fibroblasts (arrows) were noted in the PBS-injected burn control. (c) Comparison of 
initial time of CD29+, α-SMA+ cell mobilization between the SP-injected and the 
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PBS-injected group by double immunofluorescence staining with anti-α-SMA 
(FITC; green) and anti-CD29 (Texas Red; red). 10 ml PB was sequentially 
withdrawn at indicated time after the injury and attached mononuclear cells were 
fixed after the acquisition of fibroblastic morphology. Total cells were visualized by 
DAPI staining. CD29+, α-SMA+ cells were detected at 3 day post burn in the SP-
injected group but detected at 7 day in the PBS-injected burn control. (d) 
Comparison of mobilization kinetics of CD29+, CD45- cells with those of CD29-, 
CD45+ macrophage between the SP-injected and the PBS-injected group by 
double immunofluorescence staining with anti-CD45 (Texas Red; red) and anti-
CD29 (FITC; green). Mobilization of CD29-, CD45+ macrophages was not affected 
by SP injection in contrast to marked acceleration of CD29+, CD45- cell 
mobilization by SP injection. (e) SP-dose dependency of MSCsp mobilization 
kinetics. One wound per eye was made and SP was injected twice at the doses of 
0.05nmole/kg, 0.5nmole/kg, and 5.0nmole/kg SP and 10 ml PB was withdrawn 
from the same rabbit sequentially four times at 3, 5, 7, 9 days post burn. CD29+ 
cells in 10 ml PB were counted. Results shown are mean values + s. d. (n=3 in 
each group). (f) Characterization of mobilized CD29+ cells with RT-PCR. Molecular 
nature of the mobilized cells (CD29+, α-SMA+, K3+) was identical even though their 
mobilization kinetics was distinct. (g) Effect of SP dose on HSC-CFU kinetics. From 
the PB withdrawn at indicated time, HSC-CFU was measured. Results shown are 
mean values + s. d. (n=3 in each group). *P< 0.05 **P < 0.01, ***P < 0.001 versus 
the burn control. 
 
Figure 4 Accelerated wound healing by autologous MSCsp transfusion and their 
engraftment in the epithelial layer and stroma of the injured tissue. MSCsp was 
isolated from 10 ml PB of six uninjured rabbits at 3 day after SP injection 
(5.0nmole/kg) and cultured individually in the MSCGM medium for 4 weeks. After 
immunofluorescence staining and RT-PCR analysis for the confirmation of cellular 
identity (CD29+, α-SMA+, K3+, CD45-), cells were harvested and labeled with PKH 
and 5X106 MSCssp were transfused through the ear vein of four rabbits, individually, 
at 3 day after the alkali burn injury (one wound per eye). The wound healing rate in 
the transfused group was compared with that of the PBS-injected burn control as 
well as the SP-injected group (n=4 per group). (a) Gross and histological view of 
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the wound healing effect of the MSCsp cell transfusion in comparison with the SP 
injection and the PBS-injected burn control at 7 day post injury. Representative 
digital images from four individuals were shown. The original wound area was 
marked by the dotted circle. Histology of the entire area of the injured site was 
shown. cc, central cornea; Lim, limbus. At high magnification (b), rather loosely 
aggregating cells, indicative of upward migration of cells from the stroma (arrows), 
were detected in several locations at the borderline between the epithelial and 
stromal layer. (c) lmmunofluorescence staining with K3, CD29 and α-SMA Abs in 
the MSCssp transfused group, (d) in uninjured collateral side, (e) in PBS-injected 
burn control, and (f) in the SP-injected group as a positive control. Frozen sections 
were incubated with primary Abs and then FITC-labeled secondary Abs for 
concomitant detection of PKH-labeled cells in the same tissue sections. Total cells 
were visualized by DAPI staining. The PKH labeled MSCsp was observed in the 
entire corneal epithelial layer and partly in the stroma. No PKH-labeled cell was 
noted in the uninjured collateral side. PKH negative K3+ cells (*) were detected in 
the stroma of the injured region of cell transfused group, suggesting infiltration of 
endogenous MSC mobilized by the injury-induced SP. Scale bar=100μm 
 
Figure 5 Transmigration of human MSCs on 3-D collagen gel accompanied by 
concomitant induction of MMPs and inhibition of TIMPs. (a) Transmigration of 
human MSCs on the 3-D collagen gel within a millicell insert. Human MSC were 
cultured on the type IV collagen-coated type I collagen gel matrix and were 
stimulated to migrate out of the gel along the SP-gradients by daily treatment of SP 
for 3 days. The transmigration and collagen degradation was noted by the 
clearance of the opaque collagen gel and also by the histological examination of 
the cross sections. Human MSCs in the gel were noted by arrows. (b) Gelatin-
zymography of the culture supernatant. MMP-9 (92 kDa), MMP-2 (72 kDa), their 
activation-cleaved products were shown as clear zones in the gelatin-impregnated 
gel. (c) Blockade of chemoattractive transmigration of human MSC by abolishment 
of SP-gradient or NK-1 receptor blocker. To confirm chemokine-stimulated 
transmigration, the same concentration of SP (100 nM) was applied to the top 
and/or the bottom of the millicell chamber or the NK-1R blocker, L732138 (100nM) 
concomitantly with SP treatment for 3 days. (d) Effect of SP on the biosynthesis of 
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MMPs and TIMPs. Human MSCs were treated with SP and labeled with 35S-
methionine for 16h and the culture supernatants were subjected to 
immunoprecipitation with specific antibodies. (e) Effect of SP on the MT-1 MMP 
expression and membrane association of MMP-2 and TIMP-2. Triton X-100 soluble 
cell lysates were subjected to immunoprecipitation with specific Ab or western blot 
analysis. (f) Immunofluorescence staining with MT1-MMP. Human MSCs were 
treated with SP for 16 h, fixed, and stained with the MT1-MMP Ab and detected 
with FITC-conjugated secondary antibodies. MT1-MMP surface staining was 
increased by the SP treatment.  
 
Figure 6 SP-stimulated cell proliferation, biphasic ERK1/2 activation, and nuclear 
translocation of β-catenin in human MSC. (a) The tryphan blue excluded viable 
cells were counted 3 day after the SP treatment. Results shown are mean values + 
s. d. of four independent experiments. (b) BrdU labeling index after 24 h and 48 h 
SP treatment. The cells were incubated with BrdU for first 24 h or next 24 h after 
SP treatment. Results shown are mean values + s. d. of two independent 
experiments. (c) Western blot analysis with anti-phospho-ERK-1/2 and anti-pan 
ERK Ab in the cell lysates of the SP-treated human MSCs, (d) in order to 
distinguish the SP-stimulated ERK-1/2 activation from the serum-stimulated one, 
SP was treated at 24 h after the fresh medium change when the serum-stimulated 
ERK-1/2 activation has regressed to the basal level. Early ERK1/2 activation at 30 
min was followed by bigger biphasic ERK-1/2 activation at 16 h and 48 h post 
treatment. (e) PD98059 MEK inhibitor (50μM) inhibited upstream molecule for SP-
stimulated ERK-1/2 activation. (f) Western blot analysis with anti-NK-1R Ab in the 
Triton X100 soluble cell lysates. (g) SP-ELISA in the culture medium after 24 h and 
48 h treatment. SP at 100 nM remained 1/200 of original concentration and SP at 
10 nM remained 1/40 after 24 h in the MSC culture. Results shown are mean 
values + s. d. of four independent experiments. (h) Immunofluorescence staining 
with β-catenin Ab and FITC-conjugated secondary Ab. Human MSC was treated 
with SP and fixed at 48 h after SP treatment. Nuclear translocation of β-catenin 
was distinct at 48 h in all the cells of the SP 100 nM treated group. (i) ELISA for 
VEGF in the culture supernatant of SP-treated human MSCs for 48 h. Results 
shown are mean values + s. d. of two independent experiments. (j) Western blot 
analysis for fibronectin in the culture supernatant of human MSCs cultured in the 
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presence of SP for 48 h. *P< 0.05 **P < 0.01, ***P < 0.001 versus PBS-treated 
control. 
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